XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer

5-FU-based chemoradiotherapy (CRT) and oxaliplatin-based CRT are commonly used therapies for advanced colorectal cancer (CRC). However, patients with a high expression of ERCC1 have a worse prognosis than those with a low expression. In this study, we investigated the effect of XPF–ERCC1 blockers on...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ming-Yii, Huang, Yi-Jung, Cheng, Tian-Lu, Jhang, Wun-Ya, Ke, Chien-Chih, Chen, Yi-Ting, Kuo, Shih-Hsun, Lin, I-Ling, Huang, Yu-Hsiang, Chuang, Chih-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252687/
https://www.ncbi.nlm.nih.gov/pubmed/37296596
http://dx.doi.org/10.3390/cells12111475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252687/
https://www.ncbi.nlm.nih.gov/pubmed/37296596
http://dx.doi.org/10.3390/cells12111475

Ejemplares similares